Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSRIT4)

Drug Name
Lenzilumab Drug Info
Synonyms lenzilumab; GTPL8935; KB003; KB-003
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [1]
Chronic myelogenous leukaemia 2A20.0 Phase 1 [2]
Therapeutic Class
Antiviral Agents
Cross-matching ID
TTD Drug ID
DMSRIT4

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN colony-stimulating factor (GM-CSF) TTPZGYX CSF2_HUMAN Inhibitor [3]
Granulocyte-macrophage colony-stimulating factor (CSF2) TTNYZG2 CSF2_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Granulocyte-macrophage colony-stimulating factor (CSF2) DTT CSF2 3.027 3.863 3.372 4.747
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Coronavirus Disease 2019 (COVID-19)
ICD Disease Classification 1D6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Granulocyte-macrophage colony-stimulating factor (CSF2) DTT CSF2 2.36E-01 -0.06 -0.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04351152) Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.